A group of investors including New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital, led a $150m Series A round in Avenzo Therapeutics, a clinical-stage biotechnology company, with participation from INCE Capital, TF Capital, Delos Capital, and Quan Capital. “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” Athena Countouriotis, Avenzo Co-Founder, President and CEO.